Compare VNRX & RMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNRX | RMCO |
|---|---|---|
| Founded | N/A | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Multi-Sector Companies |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2M | 45.7M |
| IPO Year | N/A | N/A |
| Metric | VNRX | RMCO |
|---|---|---|
| Price | $0.27 | $4.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 2.3M | 41.7K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | ★ 0.23% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,472,007.00 | ★ $3,798,352.00 |
| Revenue This Year | $55.98 | $531.90 |
| Revenue Next Year | $420.37 | $200.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 14.48 | ★ 445.90 |
| 52 Week Low | $0.22 | $0.91 |
| 52 Week High | $0.94 | $4.76 |
| Indicator | VNRX | RMCO |
|---|---|---|
| Relative Strength Index (RSI) | 43.40 | 71.28 |
| Support Level | $0.27 | $3.90 |
| Resistance Level | $0.35 | $4.43 |
| Average True Range (ATR) | 0.03 | 0.39 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 3.83 | 63.83 |
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.